Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity

Continual and rapid mutation of seasonal influenza viruses by antigenic drift necessitates the almost annual reformulation of flu vaccines, which may offer little protection if the match to the dominant circulating strain is poor. S139/1 is a cross-reactive antibody that neutralizes multiple HA strains and subtypes, including those from H1N1 and H3N2 viruses that currently infect humans. The crystal structure of the S139/1 Fab in complex with the HA from the A/Victoria/3/1975 (H3N2) virus reveals that the antibody targets highly conserved residues in the receptor binding site and contacts antigenic sites A, B, and D. Binding and plaque reduction assays show that the monovalent Fab alone can protect against H3 strains, but the enhanced avidity from binding of bivalent IgG increases the breadth of neutralization to additional strains from the H1, H2, H13, and H16 subtypes. Thus, antibodies making relatively low affinity Fab interactions with the receptor binding site can have significant antiviral activity when enhanced by avidity through bivalent interactions of the IgG, thereby extending the breadth of binding and neutralization to highly divergent influenza virus strains and subtypes.

[1]  Giovanni Cardone,et al.  Influenza virus pleiomorphy characterized by cryoelectron tomography , 2006, Proceedings of the National Academy of Sciences.

[2]  I. Wilson,et al.  Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution , 1981, Nature.

[3]  John Steel,et al.  Protection from the 2009 H1N1 Pandemic Influenza by an Antibody from Combinatorial Survivor-Based Libraries , 2010, PLoS pathogens.

[4]  J. Lifson,et al.  Distribution and three-dimensional structure of AIDS virus envelope spikes , 2006, Nature.

[5]  J. Crowe,et al.  A Broadly Neutralizing Human Monoclonal Antibody That Recognizes a Conserved, Novel Epitope on the Globular Head of the Influenza H1N1 Virus Hemagglutinin , 2011, Journal of Virology.

[6]  Y Tateno,et al.  Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses. , 1991, Virology.

[7]  J. Yewdell,et al.  The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype) , 1982, Cell.

[8]  John Steel,et al.  Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies , 2008, Proceedings of the National Academy of Sciences.

[9]  Chih-Jen Wei,et al.  Vaccinate for the next H2N2 pandemic now , 2011, Nature.

[10]  J. Skehel,et al.  An antibody that prevents the hemagglutinin low pH fusogenic transition. , 2002, Virology.

[11]  N. S. Laursen,et al.  Highly Conserved Protective Epitopes on Influenza B Viruses , 2012, Science.

[12]  G. Air,et al.  Sequence relationships among the hemagglutinin genes of 12 subtypes of influenza A virus. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Martin H. Koldijk,et al.  A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses , 2011, Science.

[14]  Damien Fleury,et al.  Antigen distortion allows influenza virus to escape neutralization , 1998, Nature Structural Biology.

[15]  J. Skehel,et al.  Structure of influenza haemagglutinin at the pH of membrane fusion , 1994, Nature.

[16]  James E. Crowe,et al.  Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus , 2010, Science.

[17]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[18]  Gira Bhabha,et al.  Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.

[19]  Noriko Kishida,et al.  Cross-Protective Potential of a Novel Monoclonal Antibody Directed against Antigenic Site B of the Hemagglutinin of Influenza A Viruses , 2009, PLoS pathogens.

[20]  J. Skehel,et al.  A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins , 2011, Science.

[21]  Y. Guan,et al.  Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells , 2008, PloS one.

[22]  Pascal Rigolet,et al.  Structure of influenza virus haemagglutinin complexed with a neutralizing antibody , 1995, Nature.

[23]  K. Lindblade,et al.  A distinct lineage of influenza A virus from bats , 2012, Proceedings of the National Academy of Sciences.

[24]  I. Wilson,et al.  Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. West,et al.  Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10 , 2009, Proceedings of the National Academy of Sciences.

[26]  K. Subbarao,et al.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. , 2010, The Journal of clinical investigation.

[27]  J. Skehel,et al.  The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. , 1987, Annual review of biochemistry.

[28]  J. Crowe,et al.  Human Monoclonal Antibodies to Pandemic 1957 H2N2 and Pandemic 1968 H3N2 Influenza Viruses , 2012, Journal of Virology.

[29]  G. Nabel,et al.  Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination , 2010, Science.

[30]  Steven Salzberg,et al.  The contents of the syringe , 2008, Nature.

[31]  Damien Fleury,et al.  A complex of influenza hemagglutinin with a neutralizing antibody that binds outside the virus receptor binding site , 1999, Nature Structural Biology.

[32]  S. Cusack,et al.  Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid , 1988, Nature.

[33]  Surender Khurana,et al.  Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin , 2011, Proceedings of the National Academy of Sciences.

[34]  I. Wilson,et al.  Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. , 2012, Current opinion in virology.

[35]  John Steel,et al.  Cross-neutralization of influenza A viruses mediated by a single antibody loop , 2012, Nature.

[36]  Mark Wolff,et al.  Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. , 2006, The New England journal of medicine.

[37]  Ya Ha,et al.  X-ray structure of the hemagglutinin of a potential H3 avian progenitor of the 1968 Hong Kong pandemic influenza virus. , 2003, Virology.

[38]  Y. Iba,et al.  Naturally Occurring Antibodies in Humans Can Neutralize a Variety of Influenza Virus Strains, Including H3, H1, H2, and H5 , 2011, Journal of Virology.

[39]  I. Wilson,et al.  Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation , 1981, Nature.

[40]  Boguslaw Stec,et al.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses , 2009, Nature Structural &Molecular Biology.

[41]  James E Crowe,et al.  Epitope-Specific Human Influenza Antibody Repertoires Diversify by B Cell Intraclonal Sequence Divergence and Interclonal Convergence , 2011, The Journal of Immunology.